Cargando…
Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory sign...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432368/ https://www.ncbi.nlm.nih.gov/pubmed/22957259 http://dx.doi.org/10.1155/2012/648167 |
_version_ | 1782242200456790016 |
---|---|
author | Yoshimura, Koichi Aoki, Hiroki |
author_facet | Yoshimura, Koichi Aoki, Hiroki |
author_sort | Yoshimura, Koichi |
collection | PubMed |
description | Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA. |
format | Online Article Text |
id | pubmed-3432368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34323682012-09-06 Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm Yoshimura, Koichi Aoki, Hiroki Int J Vasc Med Review Article Abdominal aortic aneurysm (AAA) is a common disease causing segmental expansion and rupture of the aorta with a high mortality rate. The lack of nonsurgical treatment represents a large and unmet need in terms of pharmacotherapy. Advances in AAA research revealed that activation of inflammatory signaling pathways through proinflammatory mediators shifts the balance of extracellular matrix (ECM) metabolism toward tissue degradation. This idea is supported by experimental evidence in animal models that pharmacologic intervention at each pathological step can prevent AAA development. Previously, we identified c-Jun N-terminal kinase (JNK), a pro-inflammatory signaling molecule, as a therapeutic target for AAA. Abnormal activation of JNK in AAA tissue regulates multiple pathological processes in a coordinated manner. Pharmacologic inhibition of JNK tips the ECM balance back towards repair rather than degradation. Interventions targeting signaling molecules such as JNK in order to manipulate multiple pathological processes may be an ideal therapeutic strategy for AAA. Furthermore, the development of biomarkers as well as appropriate drug delivery systems is essential to produce clinically practical pharmacotherapy for AAA. Hindawi Publishing Corporation 2012 2012-08-21 /pmc/articles/PMC3432368/ /pubmed/22957259 http://dx.doi.org/10.1155/2012/648167 Text en Copyright © 2012 K. Yoshimura and H. Aoki. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Yoshimura, Koichi Aoki, Hiroki Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title_full | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title_fullStr | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title_full_unstemmed | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title_short | Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm |
title_sort | recent advances in pharmacotherapy development for abdominal aortic aneurysm |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432368/ https://www.ncbi.nlm.nih.gov/pubmed/22957259 http://dx.doi.org/10.1155/2012/648167 |
work_keys_str_mv | AT yoshimurakoichi recentadvancesinpharmacotherapydevelopmentforabdominalaorticaneurysm AT aokihiroki recentadvancesinpharmacotherapydevelopmentforabdominalaorticaneurysm |